Table 4.
Cox Proportional Hazards Regression for ASVD Events by the Presence of any AAC
| n (%) | Event rate (95% CI) | Unadjusted HR(95% CI) | FRS-adjusted HR (95% CI)a | |
|---|---|---|---|---|
| ASVD hospitalization and/or death (n = 420) | ||||
| No AAC (AAC24 score 0) | 96 (33.4) | 28.90 (23.66–35.30) | 1 (reference) | 1 (reference) |
| Any AAC (AAC24 score 1–24) | 324 (42.4) | 38.50 (34.53–42.93) | 1.36 (1.08–1.70) | 1.31 (1.05–1.65) |
| ASVD deaths (n = 206) | ||||
| No AAC (AAC24 score 0) | 40 (13.9) | 10.66 (7.82–14.53) | 1 (reference) | 1 (reference) |
| Any AAC (AAC24 score 1–24) | 166 (21.7) | 17.02 (14.62–19.82) | 1.65 (1.17–2.33) | 1.57 (1.11–2.23) |
| All-cause mortality (n = 377) | ||||
| No AAC (AAC24 score 0) | 85 (29.6) | 22.65 (18.31–28.02) | 1 (reference) | 1 (reference) |
| Any AAC (AAC24 score 1–24) | 292 (38.2) | 29.94 (26.70–33.58) | 1.36 (1.07–1.73) | 1.32 (1.04–1.69) |
| Coronary heart disease hospitalization and/or death (n = 231) | ||||
| No AAC (AAC24 score 0) | 50 (17.4) | 14.29 (10.83–18.86) | 1 (reference) | 1 (reference) |
| Any AAC (AAC24 score 1–24) | 181 (23.7) | 20.20 (17.46–23.37) | 1.43 (1.04–1.95) | 1.38 (1.01–1.89) |
| Myocardial infarction and/or coronary heart disease death (n = 154) | ||||
| No AAC (AAC24 score 0) | 30 (10.5) | 8.15 (5.70–11.65) | 1 (reference) | 1 (reference) |
| Any AAC (AAC24 score 1–24) | 124 (16.2) | 9.53 (10.91–15.51) | 1.64 (1.10–2.44) | 1.57 (1.05–2.34) |
| Cerebrovascular disease hospitalization and/or death (n = 63) | ||||
| No AAC (AAC24 score 0) | 33 (11.5) | 9.01 (6.40–12.67) | 1 (reference) | 1 (reference) |
| Any AAC (AAC24 score 1–24) | 142 (18.6) | 15.25 (12.94–17.98) | 1.73 (1.19–2.53) | 1.67 (1.15–2.45) |
Values in bold are p < 0.05 compared to women with no AAC.
ASVD = atherosclerotic vascular disease; AAC = abdominal aortic calcification; HR = hazard ratio; FRS = Framingham risk score.
a
Cox proportional hazards regression analyses were adjusted for general FRS plus treatment code (calcium or placebo).